Tabla 2: Muerte celular por tumor primario y tipo de quimioterapia en líquido de ascitis.

Identifi-

cación

Primario

Línea

Cisplatino

Carboplatino

Oxilaplatino

Paclitaxel

Docetaxel

Irinotecan

Topotecan

Etopósido

Doxorrubicina

Gemcitabina

5FU

AAALC3

Colangiocarcinoma

4

71.6 (2.9)

7.1 (1.4)

R

28.5 (3.0)

R

53.8 (0.4)

94.7 (0.1)

20.3 (3.4)

R

NP

NP

NP

59.6 (2.8)

24.1 (3.6)

R

LUCALC4

Colangiocarcinoma

0

45.6 (1.6)

R

6.7 (4.4)

R

35.8 (4.5)

R

47.3 (1.2)

R

87.0 (0.5)

31.5 (3.2)

R

37.2 (2.2)

R

NP

29.3 (1.8)

R

37.2 (2.2)

R

29.3 (1.8)

R

LUCALC12

Colorrectal

3

40.8 (3.5)

R

5.9 (2.1)

R

19.4 (0.9)

R

36.6 (2.2)

R

83.6 (0.4)

19.9 (3.6)

R

12.7 (9.3)

R

NP

NP

59.3 (2.0)

21.3 (2.0)

R

YDLC10

Colorrectal

2

NP

20.5 (4.6)

R

42.1 (0.8)

R

25.9 (3.2)

R

97.7 (0.7)

NP

27.7 (3.2)

R

NP

64

NP

31.8 (0.8)

R

AAALC7

Colorrectal

0

65.0 (1.4)

4.2 (4.4)

R

26.6 (3.3)

R

50.1 (4.7)

R

90.3 (1.7)

26.2 (4.9)

R

NP

NP

NP

56.8 (3.8)

27.6 (3.5)

R

AAALC10

Colorrectal

1

76.1 (1.7)

5 (4.3)

R

18 (2.8)

R

38.2 (4.8)

R

90.8 (0.3)

29.8 (3.6)

R

NP

NP

NP

56.6 (0.1)

25.3 (1.6)

R

YUSLC3

Colorrectal

2

18.7 (4.5)

R

8.3 (2.5)

R

19.4 (3.7)

R

NP

90.3 (1.1)

21.8 (3.8)

R

16 (2.9)

R

NP

NP

41.4 (1.5)

R

72.6 (1.3)

ONCOLC1

C Hepatocelular

2

77.8 (0.7)

16.6 (5.5)

R

40.6 (5.6)

R

65.8 (4.1)

R

94.6 (0.5)

44.9 (4.9)

R

NP

NP

NP

65.3 (4.6)

26.8 (4.3)

R

AAALC5

C Hepatocelular

1

70.1 (0.8)

10.0 (2.2)

R

30.2 (3.1)

R

62.1 (0.4)

94.9 (0.02)

42.1 (2.6)

R

NP

NP

NP

49.5 (2.7)

R

53.0 (0.2)

AAALC2

Mama

2

78.6 (1.1)

17.0 (3.6)

R

23.6 (3.8)

R

43.5 (2.4)

R

96.0 (0.5)

38.7 (3.8)

R

NP

NP

96.6 (0.4)

67.7 (3.6)

44.7 (2.3)

R

YDA705

Mama

2

10 (1.0)

R

NP

NP

14.0 (1.2)

R

NP

NP

NP

NP

72.0 (2.0)

NP

8.0 (1.1)

R

LUCALC13

Mama

3

69.5 (2.3)

19.2 (3.4)

R

25.1 (4.2)

R

36.2 (6.8)

R

87.8 (0.2)

15.7 (3.8)

R

15.9 (3.4)

NP

NP

NP

20 (4.3)

R

AAALC13

Mama

2

42.9 (4.9)

R

2.1 (4.2)

R

30.4 (6.1)

R

40.5 (3.2)

R

94.0 (0.2)

35.3 (0.3)

R

NP

NP

NP

57.0 (1.5)

37.1 (1.4)

R

AAALC4

Páncreas

1

NP

NP

33.7 (2.2)

R

NP

NP

34.7 (0.9)

R

NP

NP

NP

44.9 (2.8)

R

33.9 (3.0)

R

YDLCAP8

Páncreas

2

NP

NP

10.0 (1.0)

R

8.0 (1.1)

R

NP

NP

NP

NP

NP

62.0 (2.0)

4.0 (1.1)

R

LUCALC14

Páncreas

3

41 (3.2)

R

9.8 (0.4)

R

19.2 (1.9)

R

40.5 (0.5)

R

79.6 (1.1)

24.6 (3.2)

R

37.9 (6.2)

NP

NP

NP

29.5 (7.8)

R

ABCLC1

Páncreas

2

76.2 (2.7)

11.9 (3.7)

R

39.3 (2.9)

R

66.2 (5.6)

R

93.2 (0.1)

38.9 (1.9)

R

NP

NP

NP

76.08 (2.1)

58.0 (3.5)

AAALC8

Páncreas

1

36.3 (3.6)

R

2.3 (0.3)

R

27.0 (4.5)

R

32.9 (3.9)

R

89.8 (0.3)

46.3 (2.5)

R

NP

NP

NP

50.8 (1.7)

R

44.6 (1.4)

R

ABCLC6

Páncreas

2

47.7 (0.7)

R

18.5 (0.1)

R

28.5 (1.2)

R

57.0 (0.2)

90.1 (0.3)

45.1 (9.5)

R

NP

NP

NP

55.3 (0.5)

43.2 (4.8)

R

YDLCP4

Páncreas

5

30.8 (0.5)

R

NP

NP

14.0 (0.7)

R

27.0 (1.6)

R

NP

NP

NP

26.0 (2.0)

R

NP

9.0 (0.2)

R

R = resistencia = muerte celular < 50% con la dosis farmacológica 1.0X, NP = fármaco no probado, 5FU = 5 fluorouracilo.